Zentalis Pharmaceuticals, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · San Diego, CA
ZNTL chart
What traders are saying about $ZNTL
Latest postsZentalis Pharmaceuticals, Inc. news
- BlackRock Discloses 4.1% Ownership Stake in Zentalis Pharmaceuticals
Kalkine Media ·
- BlackRock reports sole voting power over 3.80M Zentalis (ZNTL) shares in a passive stake update.
Stock Titan ·
- Zentalis Pharmaceuticals, Inc. Estimates – NASDAQ:ZNTL
TradingView ·
- H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10
Moomoo ·
- Zentalis Pharmaceuticals (ZNTL) Reports Interim DENALI Study Res
GuruFocus ·
- Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
Yahoo Finance ·
- Zentalis published survival data for Zentalis Pharmaceuticals stock
ad-hoc-news.de ·
- Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
Yahoo Finance ·
- Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
investorshub.advfn.com ·
- Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Yahoo Finance ·
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Yahoo Finance ·
Zentalis Pharmaceuticals, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $67.4M | $0 | $0 |
| Net income | -$137.1M | -$165.9M | -$292.3M | -$236.8M |
| Diluted EPS | $-1.91 | $-2.33 | $-4.47 | $-4.48 |
| Total assets (year end) | $289.0M | $430.3M | $551.7M | $539.3M |
| Cash and equivalents (year end) | $36.0M | $33.9M | $28.0M | $43.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Zentalis Pharmaceuticals, Inc.
- Ticker
- ZNTL (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- SEC CIK
- 1725160
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
Frequently asked questions
What exchange is Zentalis Pharmaceuticals, Inc. listed on?
Zentalis Pharmaceuticals, Inc. trades on the Nasdaq under the ticker symbol ZNTL.
What industry is Zentalis Pharmaceuticals, Inc. in?
Zentalis Pharmaceuticals, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Zentalis Pharmaceuticals, Inc. headquartered?
Zentalis Pharmaceuticals, Inc.'s business address on file with the SEC is in San Diego, CA.
When does Zentalis Pharmaceuticals, Inc.'s fiscal year end?
Zentalis Pharmaceuticals, Inc.'s fiscal year ends on December 31.
How much revenue did Zentalis Pharmaceuticals, Inc. report?
Zentalis Pharmaceuticals, Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.